ReviewFrontiers in microbiology2023
Regulations of phage therapy across the world.
Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 1 synthesis or guideline pooled it, 143 citations in OpenAlex.
- Efficacy of phage therapy in controlling staphylococcal biofilms: a systematic review.European journal of medical research · 2025Pooled it
- Bacteriophage vB_SalS_KY05 controlsThe veterinary quarterly · 2026Article
- From laboratory to clinical application: a narrative review of bacteriophage therapy for antimicrobial-resistant infections in veterinary medicine.Veterinary research communications · 2026Review
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The Human Vaginal Virome: Composition, Microbiome Interactions, and Implications for Bacterial Vaginosis, HPV Persistence, and Preterm Birth.Microorganisms · 2026Review
- Bacteriophages in the treatment of cutaneous infections and skin disorders: therapeutic advances and future directions.Clinical microbiology reviews · 2026Review
- Review
- UropathogenicAntibiotics (Basel, Switzerland) · 2026Review
- The Therapeutic Potential of Phages in Multi-Drug Resistance Infections and Future Directions.Viruses · 2026Review
- Bacteriophages AgainstViruses · 2026Review
- Phage Therapy Enhanced by Using Engineered Bacteriophages: A Powerful Antibacterial Tool to Address the Dilemma Posed by Multidrug-Resistant Bacterial Infections.International journal of molecular sciences · 2026Review
- Chloramphenicol and tetracycline synergize with bacteriophage SeKF_13 to inactivate antimicrobial-resistantMicrobiology spectrum · 2026Article
- Regenerative Microbiology: Harnessing Bacterial Antagonism and Spatiotemporal Signaling for Diabetic Wound Repair.Smart medicine · 2026Review
- Bacteriophages as Potential Sustainable Alternatives to Antibiotics for ControllingAntibiotics (Basel, Switzerland) · 2026Review
- Integrated Morphological, Functional, and Genomic Analysis of a Novel Lytic Phage (VIT_AJPSC) Infecting Multidrug-Resistant Shigella dysenteriae.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Isolation and Genomic Characterization of a Lytic Bacteriophage Against Multidrug-ResistantViruses · 2026Article
- Reimagining Phage Therapy for MDR Pathogens: From Biobanks to Health System Integration-A Review.Infectious diseases and therapy · 2026Review
- Phages for One Health: regulatory and product life cycle considerations.Microbiology (Reading, England) · 2026Review
- Expanding the Antimicrobial Toolbox with Therapeutic Viruses: Mechanisms, Pharmaceutical Formulation, and Translational Outlook.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Isolation and Characterization of the Polyvalent Enterobacteria-Infecting Phage Cit2 with Potential for Biocontrol Applications.ACS omega · 2026Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phage therapy, a century-long treatment targeting bacterial infection, was widely abandoned after the clinical availability of antibiotics in the mid-20th century. However, the crisis of antimicrobial resistance today led to its revival in many countries. While many articles dive into its clinical application now, little research is presenting phage therapy from a regulatory perspective. Here, we focus on the regulations of phage therapy by dividing sections into Eastern Europe where it was never abandoned and Western Europe, Australia, the United States, India, and China where it only re-attracted researchers' attention in recent decades. New insights about its regulations in China are provided as little English literature has specifically discussed this previously. Ultimately, by introducing the regulations in phage therapy for human health across representative countries, we hope to provide ideas of how countries may borrow each other's adapting legislation in phage therapy to best overcome the current regulatory hurdles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.